<DOC>
	<DOC>NCT01193257</DOC>
	<brief_summary>This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy</brief_summary>
	<brief_title>Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Each patient must meet all of the following inclusion criteria: Voluntary written consent Male patients 18 years or older Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma Radiographdocumented metastatic disease Progressive disease Prior surgical castration or concurrent use of an agent for medical castration Have progressive disease during or following 1 or 2 regimens of cytotoxic chemotherapy, 1 of which must have included docetaxel. Must have received ≥ 360 mg/m2 of docetaxel within a 6month period. Patients who were clearly intolerant to docetaxel or develop progressive disease before receiving ≥ 360 mg/m2 are also eligible if they have received at least 225 mg/m2 of docetaxel within a 6month period and meet the other study entry criteria. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Even if surgically sterilized, patients must Practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, OR Abstain from heterosexual intercourse Meet screening laboratory values as specified in protocol Stable medical condition Life expectancy of 6 months or more Patients who have had up to 2 prior chemotherapy treatments are eligible to participate Patients meeting any of the following exclusion criteria are not to be enrolled in the study: Known hypersensitivity to orteronel, prednisone or gonadotropinreleasing hormone (GnRH) analogue Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone Any other therapies for prostate cancer, except for GnRH analogue therapy, must be discontinued 2 weeks before the first dose of study drug Radioisotope therapy or external beam radiation therapy within 4 weeks of first dose of study drug Documented central nervous system metastases Treatment with any investigational compound within 30 days prior ro first dose of study drug (Patients who are in longterm followup following active treatment in other trials are eligible) Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected Uncontrolled cardiovascular condition as specified in study protocol Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C Unwilling or unable to comply with protocol Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of orteronel Uncontrolled nausea, vomiting, or diarrhea despite appropriate medical therapy Patients whose prostate cancer is confined to just the prostrate bed or immediate adjacent tissue</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>